CG Oncology, Inc. Unrealized Gain (Loss) on Investments
CG Oncology, Inc. (CGON) reported Unrealized Gain (Loss) on Investments of -$4.67 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnInvestments · last filed 2026-08-06
- CG Oncology, Inc. unrealized gain (loss) on investments for the quarter ending 2026-06-30 was -$3.00M, a 259.19% decline year-over-year.
- CG Oncology, Inc. unrealized gain (loss) on investments for the quarter ending 2026-03-31 was -$1.66M, a 696.42% decline year-over-year.
- CG Oncology, Inc. unrealized gain (loss) on investments for the quarter ending 2025-06-30 was $1.89M.
- CG Oncology, Inc. unrealized gain (loss) on investments for the quarter ending 2025-03-31 was $279.00K.
| Period end | Unrealized Gain (Loss) on Investments 3 month | Unrealized Gain (Loss) on Investments 6 month |
|---|---|---|
| 2026-06-30 | -$3.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$4.67M 10-Q · filed 2026-08-06 |
| 2026-03-31 | -$1.66M 10-Q · filed 2026-05-08 | |
| 2025-06-30 | $1.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.17M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $279.00K 10-Q · filed 2026-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |